ICD 2025: New data demonstrate Nemluvio’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

来源: 编辑: 发布: 2025-06-20 14:14

An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1
Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3
This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET.

 

“These promising data go even further in highlighting the extensive benefits of Nemluvio. As this treatment becomes available in more countries around the world, it’s highly encouraging to see its robust evidence base continue to expand and strengthen.”

 

BALDO SCASSELLATI SFORZOLINI, M.D., PHD.

GLOBAL HEAD OF RESEARCH & DEVELOPMENT

GALDERMA

 

 

 

猜你还想看:

本网网友:理战  Free
评论:人不如己,尊重别人,己不如人,尊重自己。

腾讯网友:安于此生ˉ2c1
评论:等我死了,我就让我儿子给我放潇洒走一回

其它网友:风筝不会断线
评论:泰坦尼克号选在2012上映是要告诉我们,作为屌丝,就算你搞到了船票,也是死路一条。

网易网友:埖了妝女人
评论:钱多钱少,够吃就好。人丑人美,顺眼就好。人老人少,健康就好。家穷家富,和气就好。

凤凰网友:带你逃离uniVer
评论:过着八戒的生活,却想要悟空的身材。

天猫网友:﹎拿命再愛√
评论:真怀念小时候啊,天热的时候我也可以像男人一样光膀子。

搜狐网友:ヾ荆棘里的花
评论:你那么喜欢劈腿,怎么不去跳芭蕾舞。

淘宝网友:永远 ▍ Forever°
评论:领“鲜”一步

天涯网友:私念° 7/m
评论:世界上最疼痛的话是:“我爱你,但是……”。世界上最甜蜜的话是:“……但是,我爱你”。

百度网友:Pawonx-爱离殇
评论:谁说我胖我跟谁急,我不就是有点肿么。